Skip to main content
. 2020 Jul 8;5:164. [Version 1] doi: 10.12688/wellcomeopenres.16071.1

Table 3. Treatment characteristics of study population.

Characteristic All types
(n=200)		 Type I Cr.GN
(anti-GBM)
(n=31)		 Type II Cr.GN
(immune complex)
(n=93)		 Type III Cr.GN
(pauci-immune)
(n=76)		 P value
IS Yes (n (%))
     Steroids alone Yes
     Steroids plus cyclophosphamide Yes
     Steroids plus other IS Yes
     PLEX with IS Yes
             without IS Yes		 177 (88.5)
43 (21.5)
100 (50)
33 (16.5)
37 (18.5)
1 (0.5)		 22 (71)
2 (35.5)
18 (58.1)
1 (3.2)
12 (38.7)
1 (3.2)		 86 (92.5)
29 (31.2)
33 (35.4)
24 (25.8)
5 (5.4)
0		 69 (90.8)
12 (15.8)
49 (64.5)
8 (10.5)
20 (26.3)
0		 0.01
0.003
graphic file with name wellcomeopenres-5-17633-g0003.jpg
PLEX indications (n (%))
    Hemoptysis Yes
    Renal failure Yes
    Both Yes		 2 (1)
26 (13)
11 (5.5)		 1 (3.2)
10 (32)
3 (9.7)		 0
5 (5.4)
0		 1 (1.3)
11(14.5)
8 (10.5)		 graphic file with name wellcomeopenres-5-17633-g0004.jpg
Hemodialysis (n (%)) 104 (52) 25 (80.6) 32 (34.4) 47 (61.8) < 0.001

Abbreviations: IS, immunosuppression; PLEX, plasma exchange; IS, immunosuppression; CR.GN, crescentic glomerulonephritis; GBM, glomerular basement membrane.